News and Press Releases
Press releases
University of British Columbia Launched as Newest Clinical Study Site for Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
Press ReleaseToronto, Ontario – December 7, 2020, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated P...
Theralase Release 3Q2020 Financial Statements
Press ReleaseToronto, Ontario – November 27, 2020, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activat...
Theralase Granted FDA Fast Track Designation for NMIBC Phase II Clinical Study
Press ReleaseToronto, Ontario –November 23, 2020, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated P...
Theralase Technology Demonstrates High Kill Rate of Coronavirus (BSL-2)
Press ReleaseToronto, Ontario – November 13, 2020, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated ...
Theralase Releases Quarterly Newsletter
Press ReleaseToronto, Ontario – October 26, 2020, Theralase® Technologies Inc. (“Theralase” or the “Company“)(TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynam...
Theralase Announces Warrant Extension
Press ReleaseToronto, Ontario – September 30, 2020, Theralase® Technologies Inc. (“Theralase” or “Company“) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic C...
Theralase Provides Update on Bladder Cancer Study
Press ReleaseToronto, Ontario – September 24, 2020, Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Ph...
Theralase® Releases 2Q2020 Financial Statements
Press ReleaseToronto, Ontario – August 28, 2020, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated P...
Theralase Amends the Company’s Standard By-Laws
Press ReleaseToronto, Ontario – August 19, 2020, Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo D...
Theralase Signs Agreement with University of Manitoba to Commence Development of Coronavirus Vaccine and Therapy
Press ReleaseToronto, Ontario – August 19, 2020, Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo D...
in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
Let's Stay in Touch
Sign up to our newsletter to stay informed on news and updates from Theralase Technologies Inc.
